AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

The blockbuster drug Enhertu from AstraZeneca and Japanese drugmaker Daiichi Sankyo stalled the growth of a common type of breast cancer by more than a year in a large late-stage trial when used ...

HER2-negative breast cancer. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, and commercializes prescription medicines. Whereas Daiichi Sankyo Company Limited ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in another ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

THP in HER2+ metastatic breast cancer in DESTINY ... discovered by Daiichi Sankyo DSNKY DSKYF and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.